Actithera
Tuesday, February 27, 2024
Uris
Oncology
Actithera is an early-stage radiotherapeutics company with a platform for the design of Theranostics with prolonged tumor retention and rapid peripheral clearance. Its approaches have been validated in its most advanced program that has reached a well differentiated Development Candidate. Actithera is actively fundraising for its Series A in order to grow the company, its pipeline and develop its first asset.
Speakers
State
MA
Country
United States
Website
http://www.actithera.com
CEO/Top Company Official
Andreas Goutopoulos, Ph.D.
Lead Product in Development
ACT-3-19
Development Phase of Primary Product
Pre-Clinical
Number Of Unlicensed Products
1
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
)
)
)
){kind=logo}